期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非酒精性脂肪性肝病合并血脂紊乱的治疗现状 被引量：2

暂未订购
导出
摘要 非酒精性脂肪性肝病(NAFLD)患者通常合并血脂紊乱,两者同为代谢综合征的重要组分,与动脉粥样硬化及心脑血管事件密切相关。心血管疾病是合并血脂紊乱的NAFLD患者常见的死亡原因,此类患者应有效控制血脂紊乱。积极治疗血脂紊乱在心血管疾病的一级和二级预防中均起着关键作用。此文对NAFLD患者血脂紊乱的治疗现状作一综述。
作者 张舒宜 范建高
机构地区 上海交通大学医学院附属新华医院消化内科
出处 《国际消化病杂志》 CAS 2014年第1期21-24,共4页 International Journal of Digestive Diseases
基金 国家重点基础研究发展计划973项目(2012CB517501) 国家自然科学基金(81070322 81270491) 上海市科学技术委员会科研基金(09140903500 10411956300) 上海市卫生局新百人计划(XBR2011007)
关键词 非酒精性脂肪性肝病 血脂紊乱 他汀类 贝特类
分类号 R575.5 [医药卫生—消化系统]
  • 相关文献

参考文献27

  • 1Milic S,Stimac D.Nonalcoholic Fatty liver disease/steatohepatitis:epidemiology,pathogenesis,clinical presentation and treatment.Dig Dis,2012,30:158-162.
  • 2Matteoni CA,Younossi ZM,Gramlich T,et al.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology,1999,116:1413-1419.
  • 3Chatrath H,Vuppalanchi R,Chalasani N.Dyslipidemia in patients with nonalcoholic fatty liver disease.Semin Liver Dis,2012,32:22-29.
  • 4Nseir W,Mograbi J,Ghali M.Lipid lowering agents in nonalcoholic fatty liver disease and steatohepatitis:human studies.Dig Dis Sci,2012,57:1773-1781.
  • 5Rafiq N,Bai C,Fang Y,et al.Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol,2009,7:234-238.
  • 6Genest J,McPherson R,FrohlichJ,et al.2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult 2009 recommendations.Can J Cardiol,2009,25:567-579.
  • 7Dunn W,Sanyal AJ,Brunt EM,et al.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD).J Hepatol,2012,57:384-391.
  • 8Liangpunsakul S,Chalasani N.What should we recommend to our patients with NAFLD regarding alcohol use- Am J Gastroenterol,2012,107:976-978.
  • 9Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of non alcoholic fatty liver disease:practice guideline by the American Gastroenterological Association,American Association for the Study of Liver Diseases,and American College of Gastroenterology.Gastroenterology,2012,142:1592-1609.
  • 10Athyros VG,Tziomalos K,Gossios TD,et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study:a post-hoc analysis.Lancet,2010,376:1916-1922.

二级参考文献22

  • 1魏敬,蒋建东,吴锦丹,王书奎,王自正,潘淮宁,戴苏泉.盐酸小檗碱的调脂作用的研究[J].中华糖尿病杂志（1006-6187）,2005,13(1):49-51. 被引量：62
  • 2黄伟民,李宝珍.黄连素抗血小板聚集作用的临床与基础研究[J].中华血液学杂志,1989,10(5):228-231. 被引量：27
  • 3陈其明.黄连及小檗碱降血糖作用的研究[J].药学学报,1986,21(6):401-401.
  • 4徐叔云.降血脂药及抗动脉粥样硬化药的筛选法[A]..见:药理实验方法学[C].北京:人民卫生出版社,1985.781～783.
  • 5Kong WJ,Wei J,Abidi P,et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins[J]. Nat Med,200d,10 (12) : 1344-1351.
  • 6叶任高,陆再英.内科学[J].6版.北京:人民卫生出版社,2005:821-831.
  • 7Endo A. The discovery development of HMG-COA reuctase inhibitor [ J ]. J Lipid Res, 1991,33 ( 1 ) : 569.
  • 8Zhang BJ,Xu D, Guo Y,et al. Protection by and anti-oxidant mechanism of berberine against rat liver fibrosis induced by multiple hepatotoxic factors[J]. Clin Exp Pharmacol Physiol, 2008,35 (3) : 303-309.
  • 9Goldstein JL,Brown MS. Regulation of the mevalonate pathway [ J ]. Nature, 1990,343 (6257) : 425-430.
  • 10Shohz CL,Peeters AV,Hoogendijk CF,et al. Mutation- 59C-t in repeat 2 of the LDL receptor promoter: regulation in transcriptional activity and possible allelic interaction in a South African family with familial hypercholesterolaemia [ J ]. Hum Mol Genet, 1999,8 ( 1 ) : 2025-2030.

共引文献20

同被引文献23

  • 1陆伦根.非酒精性脂肪性肝病的临床特征和自然史[J].国际消化病杂志,2006,26(2):140-141. 被引量：4
  • 2窦艳玲,赵洪川.二甲双胍联合生活方式干预对非酒精性脂肪肝的治疗作用[J].中国实用内科杂志,2007,27(7):523-525. 被引量：5
  • 3Fan JG,Zhu J,Li XJ,et al.Fatty liver and the metabolic syndrome among Shanghai adults[J].J Gastroenterol hepatol,2005,20:1825-1832.
  • 4Yan J,Xie W,Ou WN,et al.Epidemiological survey and risk factor analysis of fatty liver disease of adult residents,Beijing,China[J].J Gastroenterol Hepatol,2013,28:1654-1659.
  • 5Wong VW,Wong GL,Choi PC,et al.Disease progression of non-alcoholic fatty liver disease:a prospective study with paired liver biopsies at 3years[J].Gut,2010,59(7):969-974.
  • 6Pais R,Charlotte F,Fedchuk L,et al.A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver[J].J Hepatol,2013,59:550-556.
  • 7刘玉兰.从肝肠“对话”谈肝脏疾病[J].中国医学论坛报,2010,36(44):D1.
  • 8Rong X,Li Y,Ebihara M,et al.AngiotensinⅡtype 1receptor-independent beneficial effects of telmisartan on dietary-induced obesity,insulin resistance and fatty liver in mice[J].Diabetologia,2010,53:1727-1731.
  • 9Dunn W,Sanyal AJ,Brunt EM,et al.Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease(NAFLD)[J].J hepatol,2012,57:384-391.
  • 10Liangpunsakul S,Chalasani N.What should we recommend to our patients with NAFLD regarding alcohol use?[J].Am J Gastroenterol,2012,107:976-978.

引证文献2

二级引证文献7

国际消化病杂志
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部